147 related articles for article (PubMed ID: 34636058)
1. Neuroblastoma-Telomere maintenance, deregulated signaling transduction and beyond.
Stainczyk SA; Westermann F
Int J Cancer; 2022 Mar; 150(6):903-915. PubMed ID: 34636058
[TBL] [Abstract][Full Text] [Related]
2. Targeting anaplastic lymphoma kinase in neuroblastoma.
Umapathy G; Mendoza-Garcia P; Hallberg B; Palmer RH
APMIS; 2019 May; 127(5):288-302. PubMed ID: 30803032
[TBL] [Abstract][Full Text] [Related]
3. A mechanistic classification of clinical phenotypes in neuroblastoma.
Ackermann S; Cartolano M; Hero B; Welte A; Kahlert Y; Roderwieser A; Bartenhagen C; Walter E; Gecht J; Kerschke L; Volland R; Menon R; Heuckmann JM; Gartlgruber M; Hartlieb S; Henrich KO; Okonechnikov K; Altmüller J; Nürnberg P; Lefever S; de Wilde B; Sand F; Ikram F; Rosswog C; Fischer J; Theissen J; Hertwig F; Singhi AD; Simon T; Vogel W; Perner S; Krug B; Schmidt M; Rahmann S; Achter V; Lang U; Vokuhl C; Ortmann M; Büttner R; Eggert A; Speleman F; O'Sullivan RJ; Thomas RK; Berthold F; Vandesompele J; Schramm A; Westermann F; Schulte JH; Peifer M; Fischer M
Science; 2018 Dec; 362(6419):1165-1170. PubMed ID: 30523111
[TBL] [Abstract][Full Text] [Related]
4. Whole-genome sequencing of recurrent neuroblastoma reveals somatic mutations that affect key players in cancer progression and telomere maintenance.
Fransson S; Martinez-Monleon A; Johansson M; Sjöberg RM; Björklund C; Ljungman G; Ek T; Kogner P; Martinsson T
Sci Rep; 2020 Dec; 10(1):22432. PubMed ID: 33384420
[TBL] [Abstract][Full Text] [Related]
5. Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib.
Guan J; Fransson S; Siaw JT; Treis D; Van den Eynden J; Chand D; Umapathy G; Ruuth K; Svenberg P; Wessman S; Shamikh A; Jacobsson H; Gordon L; Stenman J; Svensson PJ; Hansson M; Larsson E; Martinsson T; Palmer RH; Kogner P; Hallberg B
Cold Spring Harb Mol Case Stud; 2018 Aug; 4(4):. PubMed ID: 29907598
[TBL] [Abstract][Full Text] [Related]
6. Biological categories of neuroblastoma based on the international neuroblastoma pathology classification for treatment stratification.
Nakazawa A
Pathol Int; 2021 Apr; 71(4):232-244. PubMed ID: 33657257
[TBL] [Abstract][Full Text] [Related]
7. Too many targets, not enough patients: rethinking neuroblastoma clinical trials.
Fletcher JI; Ziegler DS; Trahair TN; Marshall GM; Haber M; Norris MD
Nat Rev Cancer; 2018 Jun; 18(6):389-400. PubMed ID: 29632319
[TBL] [Abstract][Full Text] [Related]
8. Low Frequency ALK Hotspots Mutations In Neuroblastoma Tumours Detected By Ultra-deep Sequencing: Implications For ALK Inhibitor Treatment.
Javanmardi N; Fransson S; Djos A; Sjöberg RM; Nilsson S; Truvé K; Kogner P; Martinsson T
Sci Rep; 2019 Feb; 9(1):2199. PubMed ID: 30778092
[TBL] [Abstract][Full Text] [Related]
9. Telomere Maintenance Mechanisms Define Clinical Outcome in High-Risk Neuroblastoma.
Koneru B; Lopez G; Farooqi A; Conkrite KL; Nguyen TH; Macha SJ; Modi A; Rokita JL; Urias E; Hindle A; Davidson H; Mccoy K; Nance J; Yazdani V; Irwin MS; Yang S; Wheeler DA; Maris JM; Diskin SJ; Reynolds CP
Cancer Res; 2020 Jun; 80(12):2663-2675. PubMed ID: 32291317
[TBL] [Abstract][Full Text] [Related]
10. Exceptional response to the ALK and ROS1 inhibitor lorlatinib and subsequent mechanism of resistance in relapsed
Liu T; Merguerian MD; Rowe SP; Pratilas CA; Chen AR; Ladle BH
Cold Spring Harb Mol Case Stud; 2021 Aug; 7(4):. PubMed ID: 34210658
[TBL] [Abstract][Full Text] [Related]
11. Telomere Maintenance in Pediatric Cancer.
Ackermann S; Fischer M
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31757062
[TBL] [Abstract][Full Text] [Related]
12. Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations.
Bosse KR; Maris JM
Cancer; 2016 Jan; 122(1):20-33. PubMed ID: 26539795
[TBL] [Abstract][Full Text] [Related]
13. Common genetic variants associated with telomere length confer risk for neuroblastoma and other childhood cancers.
Walsh KM; Whitehead TP; de Smith AJ; Smirnov IV; Park M; Endicott AA; Francis SS; Codd V; ; Samani NJ; Metayer C; Wiemels JL
Carcinogenesis; 2016 Jun; 37(6):576-582. PubMed ID: 27207662
[TBL] [Abstract][Full Text] [Related]
14.
Valencia-Sama I; Ladumor Y; Kee L; Adderley T; Christopher G; Robinson CM; Kano Y; Ohh M; Irwin MS
Cancer Res; 2020 Aug; 80(16):3413-3423. PubMed ID: 32586982
[TBL] [Abstract][Full Text] [Related]
15. Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome.
Padovan-Merhar OM; Raman P; Ostrovnaya I; Kalletla K; Rubnitz KR; Sanford EM; Ali SM; Miller VA; Mossé YP; Granger MP; Weiss B; Maris JM; Modak S
PLoS Genet; 2016 Dec; 12(12):e1006501. PubMed ID: 27997549
[TBL] [Abstract][Full Text] [Related]
16. Combined Inhibition of ALK and HDAC Induces Synergistic Cytotoxicity in Neuroblastoma Cell Lines.
Hagiwara K; Tokunaga T; Iida H; Nagai H
Anticancer Res; 2019 Jul; 39(7):3579-3584. PubMed ID: 31262882
[TBL] [Abstract][Full Text] [Related]
17. Telomere Trimming and DNA Damage as Signatures of High Risk Neuroblastoma.
Yu EY; Cheung IY; Feng Y; Rabie MO; Roboz GJ; Guzman ML; Cheung NV; Lue NF
Neoplasia; 2019 Jul; 21(7):689-701. PubMed ID: 31128432
[TBL] [Abstract][Full Text] [Related]
18. RAS-MAPK Pathway-Driven Tumor Progression Is Associated with Loss of CIC and Other Genomic Aberrations in Neuroblastoma.
Eleveld TF; Schild L; Koster J; Zwijnenburg DA; Alles LK; Ebus ME; Volckmann R; Tijtgat GA; van Sluis P; Versteeg R; Molenaar JJ
Cancer Res; 2018 Nov; 78(21):6297-6307. PubMed ID: 30115695
[TBL] [Abstract][Full Text] [Related]
19. Crizotinib response in a neuroblastoma patient with a constitutional mosaic anaplastic lymphoma kinase I1170N-activating mutation.
Harvey M; Irwin MS; Armstrong L; Seath K; Young S; Gershony S; Deyell RJ
Pediatr Blood Cancer; 2021 Jun; 68(6):e28916. PubMed ID: 33523537
[No Abstract] [Full Text] [Related]
20. Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways.
Shukla N; Ameur N; Yilmaz I; Nafa K; Lau CY; Marchetti A; Borsu L; Barr FG; Ladanyi M
Clin Cancer Res; 2012 Feb; 18(3):748-57. PubMed ID: 22142829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
